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1440Background: The Mosaic bioprosthesis is a third-generation stented porcine bioprosthesis combining physio-
logic fixation and a-amino oleic acid antimineralization treatment to improve durability and hemodynamic func-
tion. This single-center study reports on the performance of the Mosaic bioprosthesis in patients 65 years of age
or less and patients older than 65 years at implantation.
Methods: Between 1994 and 1999, 88 younger patients (mean age, 58 years) and 167 older patients (mean age,
72 years) were enrolled in this prospective nonrandomized clinical trial. Follow-up visits were performed after
30 days, 6 months, and annually. Cumulative follow-up was 751 patient-years in the younger group and 1223
patient-years in the older group.
Results: Mean systolic gradient increased significantly to 17.0 and 14.7 mm Hg in younger and older patients,
respectively, at their latest follow-up (P<.001). Effective orifice area values decreased significantly to 1.8 and
1.6 cm2 (P < .001). Overall, effective orifice area values were significantly higher in younger patients
(P<.001). Transvalvular regurgitation increased over time (P<.001) but remained mild or less in more than
95% of the patients. Freedom from adverse events at latest follow-up in younger and older patients, respectively,
were as follows: structural valve deterioration, 85.7% and 86.2% (P< .05); endocarditis, 87.5% and 98.5%
(P<.01); valvular thrombosis, 98.8% and 97.1% (not significant); and explantation, 68.9% and 77.9% (P<.01).
Conclusions: Hemodynamic performance is similar in both groups. In the younger patients the incidence of
structural valve disease, endocarditis, valve-related reoperation, and explantation is higher. The incidence in
structural valve deterioration in the younger patients tends to be similar or lower compared with that seen in
the literature. (J Thorac Cardiovasc Surg 2011;141:1440-8)Supplemental material is available online.Progressive tissue degeneration and calcification lead to
structural valve deterioration (SVD) in bioprostheses and
suboptimal hemodynamic performance over time. The liter-
ature shows that tissue valves implanted in younger patients
are more prone to SVD1-7 and have a shorter valve life.1,4,7
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The Journal of Thoracic and Cardiovascular Surdesign is based on the Medtronic Hancock II valve.1
Technical innovations are incorporated to improve dura-
bility and hemodynamic performance.8 Features of the
Mosaic valve are tissue fixation by means of glutaralde-
hyde,9 predilatation of the porcine aortic root, and zero
pressure fixation across the leaflets to preserve natural
leaflet morphology.10 The tissue is mounted on a low-
profile flexible polymer stent suitable for supra-annular
implantation. Furthermore, the Mosaic bioprosthesis is
treated with a-amino oleic acid that binds to the alde-
hyde fractions of the glutaraldehyde-preserved porcine
tissue by forming Schiff base covalent linkages. The
a-amino oleic acid process has been shown to reduce
porcine valve mineralization of both the leaflets and aor-
tic wall and to improve valve gradients in several animal
studies.11-13
This single-center study compares the clinical perfor-
mance, including hemodynamic data, and valve-related mor-
bidity and mortality of theMosaic bioprosthesis implanted in
patients aged 65 years or less with that of patients older than
65years. Patientswere enrolled as part of aUSFood andDrug
Administration multicenter, prospective, nonrandomized
clinical evaluation study that concluded in late 2000. Patient
follow-up was continued as part of an ongoing, long-term,
post–US Food and Drug Administration approval study.gery c June 2011
TABLE 1. Characteristics of patients aged 65 years or younger and
patients older than 65 years undergoing aortic valve replacement
with the Mosaic bioprosthesis
65 y
(n ¼ 88)
65 y
(n ¼ 167)
P
value
Sex
Male 66 (75.0%) 84 (50.3%) P<0.001
Female 22 (25.0%) 83 (49.7%)
NYHA classification
Class I 3 (3.4%) 1 (0.6%) NS
Class II 26 (29.5%) 48 (28.7%)
Class III 54 (61.4%) 96 (57.5%)
Class IV 5 (5.7%) 22 (13.2%)
Cardiac rhythm
Sinus rhythm 79 (89.7%) 151 (90.4%) NS
Atrial fibrillation 2 (2.3%) 10 (6.0%)
Heart block 3 (3.4%) 3 (1.8%)
Paced rhythm 4 (4.6%) 3 (1.8%)
Valvular lesion
Stenosis 14 (15.9%) 29 (17.4%) P<0.05
Insufficiency 20 (22.7%) 18 (10.7%)
Mixed 54 (61.4%) 120 (71.9%)
Implanted valve size
19 mm 0 (0.0%) 7 (4.2%) <.001
21 mm 7 (8.0%) 58 (34.7%)
23 mm 29 (33.0%) 62 (37.1%)
25 mm 41 (46.5%) 37 (22.2%)
27 mm 9 (10.2%) 3 (1.8%)
29 mm 2 (2.3%) 0 (0.0%)
Concomitant procedures
Coronary artery bypass 26 (29.6%) 69 (41.3%) NS
Ascending aortic
replacement/repair
13 (14.8%) 18 (10.8%) NS
Aortic root enlargement 6 (6.8%) 14 (8.4%) NS
Myotomy/myectomy 5 (5.7%) 6 (3.6%) NS
NYHA, New York Heart Association; NS, not significant.
Abbreviations and Acronyms
AF ¼ atrial fibrillation
EOA ¼ effective orifice area
NYHA ¼ New York Heart Association
SVD ¼ structural valve deterioration
SVG ¼ systolic valve gradient
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DMATERIALS AND METHODS
Patient Population and Study Design
Between February 1994 and October 1999, a total of 255 patients requir-
ing aortic valve replacement were enrolled in this prospective nonrandom-
ized study: 88 patients were 65 years of age or less (mean age, 58 8 years;
range, 23–65 years), and 167 patients were older than 65 years (mean age,
72  4 years; range, 66–82 years). Further demographic data are summa-
rized in Table 1. Patients requiring replacement of more than 1 valve or who
had a pre-existing prosthetic heart valve in another position were excluded
from the study, as were patients who had to undergo a reoperation of the
study valve.
The study was approved by the institutional ethics committee, and all
patients provided informed consent before participation.
Surgical Technique and Anticoagulation
Management
During surgical intervention, standard cardioplegia, cardiac arrest, and
crystalloid or modified blood cardioplegia were applied. Mosaic biopros-
theses were implanted in the supra-annular position with felt-armed single
stitches. All patients received unfractionated heparin by means of intrave-
nous infusion during the first 24 hours after implantation, followed by
subcutaneous injections until complete mobilization. For 3 months post-
operatively, 36 (41%) younger patients and 59 (35%) older patients re-
ceived phenprocoumon with a target international normalized ratio
range of 2.5 to 3.0. Indications for phenprocoumon treatment were perma-
nent atrial fibrillation (AF) and severely impaired left ventricular ejection
fraction (<30%).
Follow-up
Clinical performance and valve-related morbidity and mortality of the
Mosaic bioprosthesis were assessed at the early follow-up interval (before
discharge or within 30 days after implantation), the late interval (3–6
months after implantation), 1-year follow-up (11–14 months after implan-
tation), and annually thereafter. The examination included an interview,
a 12-lead electrocardiogram, and a laboratory check for hemolysis. Fur-
thermore, transthoracic echocardiographic analysis was performed for all
patients. The mean systolic valve gradient (SVG) was calculated by using
the long form of the Bernoulli equation, and the effective orifice area
(EOA) was calculated by using the continuity equation. Valve-related
morbidity and mortality were classified and reported according to the
guidelines of the Society of Thoracic Surgeons, the American Association
of Thoracic Surgery, and the European Association of Cardio-Thoracic
Surgery.14
Data are current until June 27, 2008. This provides a cumulative
follow-up of 751 patient-years in the younger group (median, 9.8 years;
maximum, 14.0 years) and 1223 patient-years in the older group (median,
7.9 years; maximum, 13.4 years). Twelve (14%) patients in the younger
group and 55 (33%) patients in the older group were lost to follow-up.
Reasons for loss to follow-up are as follows: patient refuses further
participation (n ¼ 2 vs n ¼ 20), unknown location of patient (n ¼ 8 vs
n ¼ 30), patient moved (n ¼ 2 vs n ¼ 3), and unknown reasons
(n ¼ 0 vs n ¼ 2).The Journal of Thoracic and CarStatistical Analysis
Statistical analysis was performedwith SAS statistical software, version
9.1 (SAS Institute, Inc, Cary, NC). Descriptive statistics are used to charac-
terize data on the patient population, operative data, and follow-up data.
For continuous variables, the number of patients and mean or median,
standard deviation, minimum, and maximum values are provided. Differ-
ences between age groups were analyzed by using the Student’s t test.
The effect of age over time was analyzed by using repeated-measures
analysis of variance. For categorical variables, the number and percentage
of patients are provided. Differences between age groups were analyzed by
using Pearson’s c2 or Fisher’s exact test. The effect of age over time was
analyzed by using logistic regression analysis.
Early morbidity is defined as morbidity occurring within the first 30
days after implantation. Early mortality is defined as mortality occurring
within the first 30 days after implantation or occurring more than 30
days after implantation but before hospital discharge. Early adverse event
rates are calculated as the number of patients having the event divided by
the total number of patients and expressed as a percentage. Late adverse
events are summarized by using linearized rates, calculated by dividing
the number of late events by the sum of the late patient-years, and expressed
as a percentage. Survival analysis with the actuarial Kaplan–Meier method
is used to estimate survival and freedom from valve-related adverse events.
Peto’s formula15 is used to calculate standard errors of these estimates. Thediovascular Surgery c Volume 141, Number 6 1441
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Deffect of age over time is analyzed by using log-rank testing. Adverse
events that occurred during the early and late postoperative periods are
included in the analysis.
The preoperative variables, tested for their univariate and multivariate
association with the outcomes, include sex, age (per 5-year increase),
New York Heart Association (NYHA) class IV, preoperative AF, preoper-
ative current smoker, preoperative active endocarditis, preoperative
chronic obstructive pulmonary disease, preoperative obesity, aortic valve
lesion (stenosis, insufficiency, or mixed), previous cardiac surgery, and
concomitant coronary artery bypass grafting. Multivariate analysis with
Cox multivariate regression analysis methodology was conducted to exam-
ine risk factors for long-term morbidity and mortality. The same model-
building strategy was used for all outcomes: those variables with a univar-
iate P value of less than .25 were submitted for consideration to regression
analysis by using stepwise selection to determine the independent multivar-
iate predictors of each outcome.RESULTS
Clinical Status
Fourteen years after the study’s start, 40 patients aged 65
years or less (45% of enrolled patients) and 55 patients
older than 65 years (33%) are still actively being followed.
Three to 6 months after Mosaic bioprosthesis implanta-
tion, all younger patients and all but 1 older patient
(99%) were in NYHA class I or II. At their latest follow-
up, 93% of the younger patients and 78% of the older pa-
tients were in NYHA class I or II.
At discharge, 75 (85%) younger patients and 138 (84%)
older patients were in sinus rhythm. In addition, 6 (7%)
younger patients and 17 (10%) older patients were in AF,
1 (1%) older patient had heart block, and 7 (8%) younger
patients and 9 (5%) older patients had a paced rhythm. AtFIGURE 1. A,Mean systolic gradient over time in patients aged 65 years or you
orifice area over time in patients aged 65 years or younger and in patients olde
1442 The Journal of Thoracic and Cardiovascular Surtheir latest follow-up, 30 (75%) younger patients and 35
(66%) older patients were still in sinus rhythm, 5 (13%)
younger patients and 14 (26%) older patients were in AF,
and 5 (12%) younger patients and 3 (6%) older patients
were paced. Over time, there was no difference in cardiac
rhythm distribution between age groups.
Antithromboembolic medication use after 3 to 6 months
of follow-up consisted of anticoagulant drug use (phenpro-
coumon and heparin) in 6 (7%) younger patients and 22
(14%) older patients, antiplatelet drug use (aspirin, ticlopi-
dine, and clopidogrel) in 36 (42%) younger patients and 91
(58%) older patients, and no antithromboembolic medica-
tion in 44 (51%) younger patients and 44 (28%) older pa-
tients. At their latest follow-up, 8 (20%) younger patients
and 12 (22%) older patients were using anticoagulant
drugs, 21 (53%) younger patients and 33 (60%) older pa-
tients were using antiplatelet drugs, and 11 (28%) younger
patients and 10 (18%) older patients were not using any an-
tithromboembolic medication. Over time, antithromboem-
bolic medication use significantly changed in favor of
anticoagulant treatment (P<.001), but there was no differ-
ence in treatment between age groups.Echocardiography
Three to 6months afterMosaic bioprosthesis implantation,
transthoracic echocardiographic analysis revealed a mean
SVG of 12.7  5.6 mm Hg (range, 4.8–34.0 mm Hg) in the
younger patients and 11.7  5.0 mm Hg (range, 3.0–43.1
mm Hg) in the older patients. At their latest follow-up,nger and in patients older than 65 years (time effect: P<.001). B, Effective
r than 65 years (time effect: P<.001; age group effect: P<.001).
gery c June 2011
TABLE 2. Frequency of adverse events and actuarial freedom from valve-related adverse events 4, 8, and 12 years after aortic valve replacement in
patients aged 65 years or less (n ¼ 88, 744.1 late patient-years) and patients older than 65 years (n ¼ 167, 1209.4 late patient-years)
65 y >65 y
Late events
Actuarial freedom
from event (% ± SE) Late events
Actuarial freedom
from event (% ± SE)
Adverse event No. %/patient-years 4 y 8 y 12 y No. %/patient-years 4 y 8 y 12 y
Structural valve
deterioration
7 0.9 100.0 100.0 85.7  5.1 2 0.2 100.0 100.0 98.5  1.5*
Nonstructural valve
dysfunction
2 0.3 97.7  1.6 97.7  1.6 97.7  1.6 2 0.2 98.8  0.9 98.8  0.9 94.3  4.5
Major paravalvular leak 0 0.0 100.0 100.0 100.0 0 0.0 99.4  0.6 99.4  0.6 99.4  0.6
Mismatch 2 0.3 97.7  1.6 97.7  1.6 97.7  1.6 1 0.1 99.4  0.6 99.4  0.6 99.4  0.6
Pannus formation 0 0.0 100.0 100.0 95.6  2.4 1 0.1 100.0 100.0 100.0
Endocarditis 8 1.1 96.4  2.0 95.0  2.5 87.5  4.3 2 0.2 99.4  0.6 98.5  1.1 98.5  1.1y
Thromboembolism 4 0.5 97.6  1.7 96.0  2.3 94.1  3.0 13 0.9 94.1  1.9 92.4  2.2 89.5  3.0
Permanent neurologic event 1 0.1 100.0 100.0 98.0  2.0 3 0.2 97.4  1.3 97.4  1.3 97.4  1.3
Transient neurologic event 0 0.0 100.0 100.0 100.0 5 0.4 97.3  1.4 96.4  1.6 94.8  2.2
Peripheral embolic event 1 0.1 98.8  1.2 98.8  1.2 98.8  1.2 0 0.0 100.0 100.0 100.0
Acute myocardial infarction 1 0.1 100.0 98.4  1.6 98.4  1.6 0 0.0 100.0 100.0 100.0
Valvular thrombosis 1 0.1 98.8  1.2 98.8  1.2 98.8  1.2 3 0.2 99.4  0.6 98.6  1.0 97.1  1.8
Hemolysis 0 0.0 100.0 100.0 100.0 0 0.0 100.0 100.0 100.0
Major hemorrhages 3 0.4 97.7  1.6 96.2  2.2 96.2  2.2 4 0.3 97.4  1.3 96.5  1.6 96.5  1.6
Valve-related reoperation 20 2.7 94.1  2.6 89.9  3.4 68.9  6.0 9 0.7 98.1  1.1 96.4  1.6 89.3  4.8y
Explantation 20 2.7 94.1  2.6 89.9  3.4 68.9  6.0 9 0.7 98.1  1.1 96.4  1.6 89.3  4.8y
Death 17 2.3 95.3  2.3 84.1  4.2 73.5  6.5 45 3.7 87.1  2.6 72.4  3.9 60.8  5.1*
Cardiac death 1 0.1 100.0 98.3  1.7 98.3  1.7 9 0.7 95.0  1.7 92.3  2.3 91.1  2.6*
Noncardiac death 8 1.1 97.5  1.7 90.5  3.5 87.6  4.4 22 1.8 94.1  1.9 87.2  3.1 76.5  5.2
Valve-related death 1 0.1 100.0 100.0 98.1  1.9 2 0.2 99.3  0.7 98.4  1.1 98.4  1.1
Unexplained death 7 0.9 97.7  1.6 94.6  2.6 87.0  5.9 12 1.0 98.1  1.1 91.5  2.6 88.7  3.2
SE, Standard error. *P<.05 and yP<.01, log-rank test.
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Dmean SVG had increased to 17.0 8.6 mm Hg (range, 6.0–
50.0 mm Hg) and 14.7  6.6 mm Hg (range, 5.0–31.0 mm
Hg), respectively. Mean SVG increased significantly over
time (P<.001; Figure 1, A), without a significant difference
between age groups.
EOAvalues were 2.1 0.5 and 1.9 0.6 cm2 in younger
and older patients 3 to 6 months after implantation. Over
time, EOA values decreased significantly to 1.8  0.5 and
1.6  0.5 cm2 at latest follow-up (P<.001; Figure 1, B).
Overall, EOA values were significantly higher in younger
compared with older patients (P<.001).
Transvalvular regurgitation was mild or less in more than
95% of the patients over time and comparable between the
2 groups (Figure E1). However, in both groups the percent-
age of patients with no regurgitation significantly decreased
over time, whereas the incidence of trivial and mild regur-
gitation increased over time (P<.001).
Valve-Related Adverse Events
Linearized rates for late valve-related adverse events and
actuarial freedom from valve-related adverse event percent-
ages after 4, 8, and 12 years of Mosaic bioprosthesis im-
plantation are summarized in Table 2 for younger and
older patients.The Journal of Thoracic and CarSVD. No early cases of SVD were found. During follow-
up, 7 younger patients and 2 older patients were given
diagnoses of SVD, and their valves were subsequently
explanted. Freedom from SVD over time was significantly
lower in the younger patients (P< .05; Figure 2). In the
younger group SVD was combined with isolated aortic
valve regurgitation in 2 cases, isolated stenosis in 2 cases,
and combined regurgitation and stenosis in 2 cases. Explant
analysis showed moderate to extensive mineralization at 1
or more commissures in 4 valves, extensive leaflet mineral-
ization, and thrombotic/vegetative-appearingmaterial in the
right and left coronary cusp in 1 valve and moderately thick,
thrombotic-appearing material in all cusps in the last valve.
In the older group SVD was combined with regurgitation in
1 patient and combined regurgitation and stenosis in the
other patient. Explant analysis of both explanted valves
showed moderate to extensive mineralization at 1 or more
commissures.
Nonstructural valve dysfunction. One (0.6%) early case
of nonstructural valve dysfunction, a paravalvular leak, was
diagnosed in a younger patient on day 6. The valve was ex-
planted on day 106. Four late cases of nonstructural valve
dysfunction occurred, 2 cases per age group, and these
were diagnosed by means of echocardiographic analysis.diovascular Surgery c Volume 141, Number 6 1443
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FIGURE 2. Freedom from structural valve deterioration (SVD) over time
in patients aged 65 years or younger (solid line) and in patients older than
65 years (dashed line).
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DIn the first younger patient the valve was explanted due to
patient–bioprosthesis mismatch on day 34. In the second
younger patient mismatch was diagnosed on day 139. The
valvewas explanted due to valvular thrombosis 2.4 years af-
ter implantation. In the first older patient the mismatched
Mosaic bioprosthesis, as diagnosed on day 135, was still
in place until his death from pneumonia 6.9 years after im-
plantation. In the second older patient nonstructural valve
dysfunction caused by pannus formation was diagnosed,
and the valve was explanted 11.3 years after implantation.
Freedom from nonstructural valve dysfunction was similar
in younger and older patients.
Endocarditis. No early and 10 late cases of endocarditis
were observed, 8 cases in the younger group (range, 0.7–
9.8 years after implantation) and 2 cases in the older group
(1.7 and 5.2 years after implantation, respectively). In the
younger group Streptococcus species was isolated in 3 pa-
tients, whereas no bacterium was reported in the other 5 pa-
tients. In the older group Streptococcus species was isolated
in 1 patient and Enterococcus species was isolated in the
other patient. All patients had their infected valves ex-
planted. Freedom from endocarditis was significantly lower
in the younger group (P<.01, Table 2).
Thromboembolism. Two (1.2%) early cases of thrombo-
embolism occurred, both in the older group. One patient
was considered to have paroxysmal AF, and this patient
had a stroke during heparin treatment on postoperative
day 7. The other patient was considered to have permanent
AF, and this patient had a transient ischemic attack on post-
operative day 13. In addition, 4 late thromboembolic events
occurred in the younger group (range, 2.1–9.3 years after1444 The Journal of Thoracic and Cardiovascular Surimplantation), and 13 events occurred in the older group
(range, 0.2–9.1 years after implantation). In the younger
group thromboembolic events involved 1 permanent neuro-
logic event, 1 peripheral thromboembolic event, 1 myocar-
dial infarction, and 1 valvular thrombosis. In the older group
thromboembolic events involved 3 permanent neurologic
events, 5 transient ischemic events, and 3 thrombosed
valves. In the younger patient valvular thrombosis was diag-
nosed during aspirin treatment 2.4 years after implantation.
The thrombosed valve was replaced with a mechanical
valve. Analysis of the explanted valve showed extensive
thrombosis but no signs of cuspal degeneration, calcifica-
tion, or infection. In the older patients the first case of val-
vular thrombosis was diagnosed on postoperative day 87.
Phenprocoumon had been discontinued on day 24 because
of recurrent hemorrhage. The thrombosed valve was re-
placed with a Hancock II bioprosthesis that thrombosed
during the early postoperative course as well and was
replaced with a mechanical valve. The other 2 cases of
valvular thrombosis were diagnosed during aspirin treat-
ment 5.0 and 9.0 years after implantation, respectively.
The thrombosed valves were replaced with a mechanical
valve and a second Mosaic bioprosthesis. Explant analysis
of all 3 Mosaic valves and the Hancock II valve revealed
thrombotic-appearing material without signs of calcifica-
tion and infection in all 4 valves. Freedom from thrombo-
embolism or any of its subcategories was similar between
age groups.
Major hemorrhages. In both age groups 1 early case of
major hemorrhage occurred (1.1% vs 0.6%): a severe car-
diac tamponade 23 days after surgical intervention in
a younger patient and a severe epistaxis 24 days after surgi-
cal intervention in an older patient. Both events occurred
with phenprocoumon treatment. Furthermore, there were
3 late major hemorrhages (range, 0.3–5.8 years after im-
plantation) observed in 2 younger patients: a gastrointestinal
bleed in 1 patient and both a nonacute pleural effusion on
postoperative day 100 and severe hematoma of the thigh af-
ter an accident 5.8 years after Mosaic bioprosthesis implan-
tation in the second patient. Four late major hemorrhages
were observed in 4 older patients (range, 0.4–5.8 years after
implantation): cerebral hematoma in 2 patients and gastro-
intestinal hemorrhage in 2 patients. There was no difference
in freedom from major hemorrhage between age groups.
Hemolysis. No cases of hemolysis were reported for either
group.
Valve-related reoperation and explantation. No early
Mosaic bioprosthesis–related reoperations and explanta-
tions occurred. In the younger group 20 late valve-related
reoperations occurred (range, 0.1–10.9 years after implan-
tation), all resulting in explantation. Reasons for explanta-
tion were endocarditis in 8 patients, SVD in 7 patients,
nonstructural valve dysfunction in 1 patient, and valvular
thrombosis in 1 patient. In addition, 3 valves were replacedgery c June 2011
Rieß et al Acquired Cardiovascular Diseaseincidentally because of ascending aortic aneurysm. One pa-
tient died after reoperation for endocarditis. In the older
group 9 valves were explanted 0.2 to 12.4 years after im-
plantation. Reasons for explantation were valvular throm-
bosis in 3 patients, endocarditis in 2 patients, SVD in 2
patients, and nonstructural valve dysfunction in 2 patients.
Freedoms from valve-related reoperation and explantation
were significantly lower in younger patients (P<.01).A
C
DSurvival
No younger but 3 (1.8%) older patients died within 30
days after surgical intervention or before discharge. All 3
deaths were classified as cardiac deaths. Causes of death
were hypertrophic obstructive cardiomyopathy with left
ventricular outlet obstruction on postoperative day 3, acute
pericardial tamponade caused by aortic dissection and per-
foration on postoperative day 13, and biventricular heart
failure on postoperative day 36. In the younger group 17
late deaths occurred: 1 cardiac death, 8 noncardiac deaths,
1 valve-related death, and 7 unexplained deaths. The valve-
related death was a 49-year old man who died 8.5 years
after implantation because of low output syndrome after
Mosaic explantation for endocarditis. In the older group
45 late deaths occurred: 9 cardiac deaths, 22 noncardiac
deaths, 2 valve-related deaths, and 12 unexplained deaths.
The first valve-related death consisted of a 66-year old
man with a cerebral hemorrhage while taking phenprocou-
mon for permanent AF who had septicemia after a relieving
operation 5.8 years after implantation. The second valve-
related death was a 68-year-old man who died from heart
failure 2.7 years after implantation after having a stroke.TABLE 3. Risk ratio and 95%CI for independent predictors of morbidity a
older than 65 years
All (n ¼ 255)
Risk factor Risk ratio 95% CI P value Ri
Structural valve disease
Age (per 5-y increase) 0.64 0.50–0.84 .011
Nonstructural valve dysfunction
NYHA class IV – – NS
Endocarditis
Age (per 5-y increase) 0.71 0.55–0.90 .006
Active endocarditis 9.14 1.66–50.4 .011
Thromboembolism – – NS
Valvular thrombosis – – NS
Valve explantation
Age (per 5-y increase) 0.73 0.63–0.85 .000
Death
Age (per 5-y increase) 1.31 1.08–1.60 .007
Current smoker 2.07 1.16–3.69 .014
Male sex 1.83 1.03–3.25 .038
NYHA class IV – – NS
Preoperative AF – – NS
CI, Confidence interval; NYHA, New York Heart Association; AF, atrial fibrillation.
The Journal of Thoracic and CarNo autopsywas performed in any of these patients. Freedom
from valve-related or unexplained death at latest follow-up
was similar in younger and older patients (78.8%  8.4%
vs 87.3% 3.2% [older patients]; Figure E2 and Table 2).DISCUSSION
This single-center study compares the clinical perfor-
mance of the Mosaic bioprosthesis implanted in patients
aged 65 years or lesswith that of patients older than 65 years.
The data of annual prospective standardized echocardio-
graphic follow-up presented here are unique to this study
cohort. Mean SVG, EOA, and transvalvular regurgitation
significantly changed over time in both age groups. How-
ever, the magnitude of the changes did not affect the hemo-
dynamic performance of the Mosaic valve and was
comparable with data reported in earlier Mosaic series8,16,17
or other frequently implanted tissue valves.18-20 EOAvalues
were significantly higher in younger patients. This can be
explained by the larger valve size implanted in this group.
In our study population 7 younger and 2 older patients had
SVD, resulting in a significantly lower freedom from SVD
in the younger patients (after 12 years, 85.7%  5.1% vs
98.5%  1.5%; at latest follow-up, 85.6%  5.1% vs
86.2%  11.6%; Figure 2). Other studies showed a clear
age effect for patients younger and older than 65 years of
age as well. Aupart and colleagues5 reported a 13-year free-
dom from SVD of approximately 87% in patients less than
60 years of age, 94% in patients aged 60 to 70 years, and
approximately 97% in patients older than 70 years after
Perimount implantation. Reported 15-year freedom from
SVD rates were 75% versus 100%6 and 76% versusnd mortality in all patients, patients aged 65 years or less, and patients
65 y (n ¼ 88) 65 y (n ¼ 167)
sk ratio 95% CI P value Risk ratio 95% CI P value
0.71 0.51–0.99 .047 – – NS
18.6 1.16–298 .039 – – NS
– – NS – – NS
12.8 2.55–64.5 .002 – – NS
– – NS – – NS
– – NS – – NS
0.68 0.54–0.85 .000 – – NS
– – NS – – NS
3.55 1.35–9.35 .010 – – NS
– – NS – – NS
4.84 1.06–22.1 .042 – – NS
– – NS 3.00 1.05–8.57 .040
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15-year freedom from SVD for the Carpentier–Edwards
Supraannular Valve was 54% versus 92%.6 Compared
with the other studies, the Mosaic bioprosthesis seems to
have a similar to higher durability in patients aged 65 years
or less, but additional studies and longer follow-up are nec-
essary to verify this. For older patients, the Mosaic biopros-
thesis has similar durability as other valves when looking at
the 12-year freedom from SVD value, but it tends to do
worse when referring to the 13-year value. However, be-
cause of the 12% standard error on this value, we cannot
make valid assumptions at this follow-up interval. Indepen-
dent of age, freedom from SVD for other bioprosthetic
valves in the aortic position ranged from 70% to 85% after
15 years of implantation,1,6,21,22 suggesting that the Mosaic
bioprosthesis’ SVD rates are on the upper range of reported
values. In line with the literature,1,6 multivariate regression
analysis showed that an increase in age had an independent
protective effect on SVD development in both the complete
study group and patients aged 65 years or less (bothP<.05),
whereas this effect had disappeared in patients older than 65
years (Table 3). This was probably due to the limited number
of SVD cases in the elderly.
The first case of SVD in our group occurred after 8.4 years
of implantation in the younger group and after 9.1 years of
implantation in the older group (Figure 2). In comparison,
SVD was most commonly reported after approximately 5
years of implantation for the Intact valve,23 the Hancock II
valve,1,6,21 theMosaic valve,24 and the Carpentier–Edwards
pericardial bioprosthesis.3-5
Eight younger patients and 2 older patients had endo-
carditis, resulting in a significantly lower freedom from
endocarditis rate in the young (88% vs 99%). This is
in line with Aupart and colleagues,5 who showed that af-
ter 20 years of follow-up, 6% of the patients younger
than 60 years of age, 3% of the patients aged 60 to 70
years, and 1% of the patients older than 70 years had en-
docarditis. Multivariate regression analysis showed that
an increase in age had an independent protective effect
on the development of endocarditis in the complete study
group (P<.01). In addition, preoperative active endocar-
ditis was a significant risk factor for endocarditis after
Mosaic implantation both in the complete study group
(P < .05) and in patients aged 65 years or younger
(P<.01, Table 3). Because we only have a limited num-
ber of endocarditis cases in patients older than 65 years,
this might have hampered our efforts to find any indepen-
dent effects.
The overall freedom from infective endocarditis after
Mosaic bioprosthesis implantation is similar to that re-
ported for other stented porcine and pericardial valves,
such as the Hancock II valve,1,21 the Perimount valve,18
the Biocor valve,25 the Intact valve,23 and the Carpentier–
Edwards standard prosthesis,4 ranging from 91% to 98%.1446 The Journal of Thoracic and Cardiovascular SurBecause all valves with SVD and endocarditis were ex-
planted and these rates were higher in the younger group,
it is obvious that the incidence of reoperation and explanta-
tion was also significantly higher in patients aged 65 years
of younger. Freedom from explantation at latest follow-up
was 68.9%  6.0% and 77.9%  11.3% in younger and
older patients, respectively. This is in line with explantation
rates of other valves. Rizzoli and associates21 reported a 15-
year freedom from explantation in patients receiving the
Hancock II valve of 56% for patients aged less than 60
years and 90% for patients 60 years or older. Chan and cow-
orkes7 reported a 15-year freedom from explantation in pa-
tients with bioprosthetic valves of 45% in patients aged 51
to 60 years, 78% in patients aged 61 to 70 years, and 93%
in patients older than 70 years. Others also showed a signif-
icant inverse relationship between age of implantation and
incidence of explantation in patients receiving the Hancock
II valve1 and the Carpentier–Edwards standard valve.4 In
line with the literature, multivariate regression analysis
showed that an increase in age had an independent protec-
tive effect on valve explantation in both the complete study
group and patients aged 65 years or less (both P<.001),
whereas this effect disappeared in the elderly (Table 3).
Freedom from nonstructural valve dysfunction was com-
parable between the groups (98% vs 94%). Barratt-Boyes
and colleagues23 reported an age-independent 10-year free-
dom from nonstructural valve dysfunction of 95% for aortic
and mitral valves combined, primarily because of perivalv-
ular leaks. Our series consisted of 1 paravalvular leak, 3
mismatched valves (1 of which had to be explanted for
that reason), and 1 valve with pannus formation. Multivar-
iate regression analysis showed that patients aged 65 years
or less with an NYHA class of IV had a significantly higher
chance of nonstructural valve dysfunction (P < .05),
whereas this effect was not present in the complete group
and in patients older than 65 years (Table 3).
Four thromboembolic events occurred in the younger
group, and 13 such events occurred in the older group,
but there was no significant difference between age groups
in the incidence of thromboembolism or any of its subcat-
egories (Table 2). Multivariate regression analysis also did
not show any independent risk factors for thromboembolic
events (Table 3). Aupart and colleagues5 also reported no
age effect after Perimount implantation. In the younger
group 1 case of valvular thrombosis occurred without obvi-
ous cause. In the older group 3 cases of valvular thrombosis
occurred. The first patient was a 73-year-old woman who,
after explantation of theMosaic bioprosthesis on postoper-
ative day 87, was given a diagnosis of a congenital anti-
thrombin deficiency. The residual antithrombin III
activity of only 20% can be considered the primary cause
of this thrombosis. The second patient was a 67-year-old
man who had valvular thrombosis 5 years after implanta-
tion. Early postoperatively, this patient had acutegery c June 2011
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quired antithrombin III deficiency that had to be treated
with recombinant hirudin (Lepirudin;h l; Pharmion, Boulder,
Colo). The overlapping treatment with phenprocoumon had
to be stopped early because of a gastrointestinal hemorrhage.
Intraoperative findings and histological investigation of the
explanted Mosaic bioprosthesis supported the theory of
heparin-induced thrombocytopenia. For the last case of
valvular thrombosis, there was no obvious explanation. In
the literature the overall incidence of bioprosthesis thrombo-
sis is comparable with ours, although freedom from valvular
thrombosis is not frequently given.1,2,21,23 Multivariate
regression analysis did not find an independent risk factor
for valvular thrombosis (Table 3).
Our survival rate of 61% (vs 68%) in the elderly favors
that of David and associates,1 who showed a 15-year sur-
vival rate after Hancock II implantation of 65% in patients
aged less than 65 years and 30% in patients 65 years or
older. Multivariate regression analysis showed that increase
in age (P<.01), being a preoperative current smoker, and
male sex (both P<.05) were independent risk factors for
death in the overall group. In patients 65 years of age or
less, being a preoperative current smoker (P ¼ 0.01) and
NYHA class IV (P<.05) were independent predictors for
death, whereas in patients older than 65 years, preoperative
AF was an independent predictor for death (P<.05, Table
3). Interestingly, there is quite an overlap with the mortality
risk factors found by David and associates,1 who also
showed an independent effect for age and NYHA class IV
in all patients and age, male sex, and preoperative AF in pa-
tients without concomitant coronary artery bypass grafting.
In addition, David and associates showed that coronary ar-
tery disease, active endocarditis, and left ventricular ejec-
tion fraction of less than 40% were independent risk
factors for death. The first 2 factors were not significant in
our analysis, whereas the latter was not included in our anal-
ysis. Freedom from valve-related or unexplained death was
comparable between groups (79% vs 89%). However,
Chan and coworkers7 showed that freedom from valve-
related death after 15 years of bioprosthesis implantation
was lower in older patients: 92% in patients aged 51 to
60 years, 83% in patients aged 61 to 70 years, and 78%
in patients older than 70 years. Two Hancock II studies
show an overall freedom from valve-related and unex-
plained death rate of 71% to 92% after 15 years, which
is in line with our findings.1,21
In conclusion, the Mosaic bioprosthesis shows compara-
ble hemodynamic performance over time in younger and
older patients. In patients aged 65 years or less, the inci-
dence of SVD, endocarditis, and valve-related reoperation
and explantation is higher compared with that seen in pa-
tients older than 65 years. The incidence of SVD in the
younger patients tends to be lower compared with that
seen in the literature. However, continued clinical follow-The Journal of Thoracic and Carup is required to examine whether the durability of the Mo-
saic bioprosthesis is similar or better compared with that of
other bioprosthetic valves.References
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FIGURE E1. Mosaic bioprosthesis regurgitation over time in patients
aged 65 years or younger and in patients older than 65 years (time effect:
P<.001).
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FIGURE E2. Survival over time in patients aged 65 years or younger
(solid line) and in patients older than 65 years (dashed line).
Rieß et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 6 1448.e1
A
C
D
